VAXNEUVANCE (Merck Sharp & Dohme (Australia) Pty Ltd)
Product name
VAXNEUVANCE
Date registered
Evaluation commenced
Decision date
Approval time
196 (255 working days)
Active ingredients
Pneumococcal purified capsular polysaccharides
Registration type
EOI
Indication
VAXNEUVANCE is indicated for active immunisation for the prevention of pneumococcal disease caused by Streptococcus pneumoniae serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F) in adults and children from 6 weeks of age.